India is expected to see an upward trajectory in deal activity in 2024, according to a report by Bain & Company's Global Healthcare Private...

Glenmark had gross debt of ₹3,765 crore as of June 30, 2022. The company over the years accumulated debt to fund its innovation-led R&D and...

After the success of the covid vaccine, BioNTech is planning to return €2bn to shareholders. BioNTech will continue the clinical trial to b...

“This is an important milestone for SPARC. The licensing of antibodies from Biomodifying will assist us in our endeavour to transition SPAR...

Exclusive interview with Sunder Genomal, Managing Director, Page Industries and Glenn Saldanha, Chairman and MD, Glenmark Pharmaceuticals

Glenmark’s consolidated net profit saw a deep cut, dropping 78 per cent to Rs. 104.7 crore.

Shares of Glenmark Pharmaceuticals were trading at Rs 867 in the afternoon trade, up 0.05 per cent from the previous close on BSE.

Glenmark has completed the pre-clinical evaluation for its bi-specific antibody GBR 1302 and filed the phase I trial application for the sa...

A BILL to give effect to the financial proposals of the Central Government for the financial year 2011-2012. Be it enacted by Parliament in...